4-溴-2-(氰基甲基)苯甲酸 | 942935-70-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-(氰基甲基)苯甲酸
• 英文名称: 4-bromo-2-(cyanomethyl)benzoic acid
• CAS: 942935-70-8
• 化学式: C₉H₆BrNO₂
• 分子量: 240.056
• InChiKey: CNICEBGPOTZLOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  61.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  4-溴-2-(氰基甲基)苯甲酸 在 劳森试剂 、 甲醇 、 4-二甲氨基吡啶 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium tetrahydroborate 、 potassium acetate 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 cobalt(II) chloride 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.83h， 生成 tert-butyl N-[2-[2-(5-methyl-1,3,4-thiadiazol-2-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]carbamate
  参考文献：
  名称：

  Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c00736
• 作为产物：
  描述：

  sodium cyanide 、 5-溴苯酞 以 二甲基亚砜 为溶剂， 反应 4.0h， 生成 4-溴-2-(氰基甲基)苯甲酸
  参考文献：
  名称：

  Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B

  摘要：

  The cell division cycle 25B dual specificity phosphatase (Cdc25B) regulates the normal progression of the mammalian cell cycle by dephosphorylating and activating cyclin-dependent kinase (Cdk) complexes, particularly in response to DNA damage. Elevated Cdc25B levels enable a bypass of normal cell cycle checkpoints, and the overexpression of Cdc25B has been linked to a variety of human cancers. Thus, Cdc25B is an attractive target for the development of anticancer therapeutics. Herein we describe the synthesis and biological evaluation of a series of non-quinoid inhibitors of Cdc25B containing the 3-aminoisoquinolin-1(2H)-one pharmacophore. In addition to several strategies that address specific substitution patterns on isoquinolines, we have applied a regioselective Pd-catalyzed cross-coupling methodology to synthesize a new lead structure, 6-(3-aminophenyl)-3-(phenylamino) isoquinolin-1(2H)-one (13), which proved to be a reversible, competitive Cdc25B inhibitor with a K-i of 1.9 mu M. Compound 13 prevented human cancer cell growth and blocked Cdc25B-mediated mitotic checkpoint bypass. Molecular docking studies support binding near the catalytic site. (C) 2015 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2015.01.043

文献信息

• Isoquinoline aminopyrazole derivatives
  申请人：Chen Li

  公开号：US20070179151A1

  公开（公告）日：2007-08-02

  The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.

  本发明涉及式I的化合物：其药学上可接受的盐或酯，对映体形式，非对映异构体和外消旋体，以及制备这些化合物，含有它们的制药组合物和其制造，以及在控制或预防癌症等疾病中使用这些化合物的用途。
• ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1966190A1

  公开（公告）日：2008-09-10
• US7572809B2
  申请人：——

  公开号：US7572809B2

  公开（公告）日：2009-08-11
• [EN] ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS D'AMINOPYRAZOLE DE TYPE ISOQUINOLÉINE, LEUR FABRICATION ET APPLICATION EN TANT QU'AGENTS PHARMACEUTIQUES POUR LE TRAITEMENT DU CANCER
  申请人：HOFFMANN LA ROCHE

  公开号：WO2007071348A1

  公开（公告）日：2007-06-28

  [EN] Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
  [FR] La présente invention a pour objet les composés de formule (I), leurs sels de qualité pharmaceutique, leurs formes énantiomères, leurs diastéréoisomères et leurs racémates, la synthèse des composés susmentionnés, les médicaments les contenant et leur fabrication, ainsi que l'emploi des composés susmentionnés dans le contrôle ou la prévention de maladies telles que le cancer.